Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi


  • Niharika SwainEmail author
  • Rashmi Maruti Hosalkar
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101998


Historical Background

The human survivin gene was first cloned and described by Ambrosini et al. in 1997 as a unique and smallest member of inhibitor of apoptosis protein family (IAP) (Ambrosini et al. 1997). IAPs are diverse group of signaling molecules with wide range of physiological role, from the inhibition of apoptosis to cell cycle progression. IAPs have nine family members: X-linked IAP, cIAP1, cIAP2, neuronal apoptosis inhibitor protein, melanoma IAP, IAP-like protein 2, livin, apollon, and survivin. The first IAP was isolated as a baculovirus gene product and identified by the presence of baculovirus IAP repeat (BIR). All the members of IAP family are generally characterized by presence of one or more copies of BIR at N-terminus and ring finger domain at their carboxyl...

This is a preview of subscription content, log in to check access.


  1. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22:8581–9. doi:10.1038/sj.onc.1207113.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3(8):917–21.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Chen X, Duan N, Zhang C, Zhang W. Survivin and tumorigenesis: molecular mechanisms and therapeutic strategies. J Cancer. 2016;7(3):314–23. doi:10.7150/jca.13332.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissue. Mol Cancer Ther. 2006;5(5):1087–98.PubMedPubMedCentralCrossRefGoogle Scholar
  5. Garg H, Suri P, Gupta JC, Talwar GP, Dubey S. Survivin: a unique target for tumor therapy. Cancer Cell Int. 2016;16:49. doi:10.1186/s12935-016-0326-1.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Jaiswal PK, Goel A, Mittal RD. Survivin: a molecular biomarker in cancer. Indian J Med Res. 2015 Apr;141(4):389–97. doi:10.4103/0971-5916.159250.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Li F. Survivin study: what is the next wave? J Cell Physiol. 2003;197(1):8–29.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer. 2005;92(2):212–6.PubMedPubMedCentralCrossRefGoogle Scholar
  9. Li F, Yang J, Ramnath N, Javle MM, Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer J Int du Cancer. 2005;114(4):509–12. doi:10.1002/ijc.20768.CrossRefGoogle Scholar
  10. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Mol Pathways Clin Cancer Res. 2008;14(16):5000–5. doi:10.1158/1078-0432.CCR-08-0746.CrossRefGoogle Scholar
  11. Zhang M, Yang J, Li F. Transcriptional and posttranscriptional controls of survivin in cancer cells: Essential interfaces for developing novel approaches for cancer treatment. J Exp Clin Cancer Res: CR. 2006;25(3):391.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.MGM Dental College and HospitalNavi MumbaiIndia
  2. 2.Indian Association of Oral and Maxillofacial PathologistsAndheriIndia
  3. 3.Maharashtra State Dental CouncilMumbai, MaharashtraIndia